Tag: PROW

OXBT, PROW, RNN, BYD & Extended Watchlist

Oxygen Biotherapeutics, Inc. OXBT
–
Our readers who have been with us since October will remember OXBT, and that we were fortunate enough to catch it at a low of 1.46 before it steamrolled its way up to 11.40, affording us the chance at gains of 681% We re-tagged it on December 19thafter the consolidation off of the initial spike brought the stock back to find a bottom at 4.20. Our timing on that alert ended being spot-on, as the pattern reversed and OXBT began to ascend once more. As of Friday, the stock had reached a high of 7.40, which represents a gain of 76% from the recent 4.20 low.High volume and a strong close at 7.35 for Friday’s session will ensure OXBT a spot on our watchlists as we kick off this new trading week.

Progress Watch Corp. PROW

We pointed out the Golden Cross in progress for PROW on Friday, and despite already having witnessed gains in excess of 515% from .0065 to Thursday’s high of .04 (Initial alert- 12/20/13) we were able to reap further profits as the stock continued to uptrend, topping out at .048 and settling back only slightly to close at .0472. That high pushed our max gains on PROW to 638% in less than a month’s time. Congrats to anyone to has been able to take advantage of this rapid-gainer.

As is the case with any stock that rises so quickly, we’ll need to execute our trades with tight stops, and be on the lookout for signs of a reversal while still remaining open to the possibility of a continued breakout.

Rexhan Pharmaceuticals, Inc. RNN

We’ve followed RNN from December 11th (Low .4026) onward, and have been duly rewarded for our persistence. Friday, we reminded everyone to be on the lookout for more solid gains, as we had already followed the stock up over 90% and were witnessing some heavy pre-market trading pushing the price even higher. RNN would go on to touch a new high for us at 1.19, which represents a gain of 196% from our initial alert low from just a month ago.

This took place on well over 15x the 3mo. average volume, with a healthy close at 1.14, so we’ll be watching RNN carefully today. Like our previously mentioned plays, RNN has been gaining a lot of ground over a short period of time, and should be monitored closely. Perhaps more so than the others, a quick peek at the chart shows it beginning to look overbought. Vigilance is key! In the event of a pullback, we’d like to see RNN hold support somewhere above the .80-level.

Boyd Gaming Corp. BYD

We want to add BYD to our watchlist today. We haven’t mentioned this one before, but are interested in both the building chart, and the sector in which the company operates. BYD operates over twenty gaming entertainment properties across Nevada, New Jersey, Illinois, Indiana, Iowa, Kansas, Louisiana and Mississippi.

Gaming stocks were a hot ticket in 2013, and with online gaming now being permitted in Nevada, Delaware, and New Jersey, some folks believe that national regulation is ‘in the cards’. The gaming sector, both online and brick-and-mortar, is going to be one to watch intently in 2014.

Extended Watchlist:
BLDR, AAPL, GOGO

PROW, RNN & Extended Watchlist

Record-Setting ‘Green Rush’ Begins to Subside
–
Like all good things, the frenzied buying of countless pot stocks largely came to an end during yesterday’s session. It was a historic week; an overwhelming trend caused by sheer excitement over Colorado’s precedent-setting entry into the post-prohibition era, and we were happy to cover every step, taking profits along the way! Granted, the main wave of hysteria is now over, but our continued interest in the sector as a whole will not wane. As we stated previously, this story has only just begun to be written. Even as many of the huge runners we’ve tracked began to pull back, others maintained their trends, and still others came down to find support only to rebound and provide bounce opportunities. Rest assured, we will remain hot on the trail of any possible chance at added profits within this sector that has been so good to us for so long a time. For now, it’s time to shift gears and talk about some of our other interests that were forced to the back burner in all the excitement.

Progress Watch Corp. PROW

PROW has brought us some really impressive gains in the short time that we’ve been including it in our reports. When we first began talking about it (12/20/13, trading at .0065) we were especially interested in its tight share structure. That day, we said that the 50DMA rising sharply toward the 200DMA “should lead to a golden cross in the weeks and months ahead.”  That golden cross is now in progress as the stock ran into the close yesterday, attaining four cents, an increase of 515% off of the bottom we observed just twelve trading sessions ago.

As the value of the stock increases, we’re going to be looking for support levels to hold at areas of previous resistance. In the event of any pullbacks, we would like to see support hold at .025, and below that, .013, in order to remain bullish on PROW.

Rexhan Pharmaceuticals, Inc. RNN

Back on December 11th, we tagged RNN for the first time in our extended watchlist, and were rewarded with an intraday run of 26% from .4026 to  .5179. Even as marijuana stocks were breaking out over the past couple of days, we were still tracking this stock’s impressive run via our extended watchlists, and yesterday, saw a high of .765. That marks an increase of 90% from our observed low, a figure which is being pushed even higher this morning; pre-market trades have gone off as high as .929, so things could get very interesting from here. This spike seems to have been catalyzed by a recent press announcement from RNN.


The following PR was released under the headline: “RX-3117 has Shown Efficacy Against Gemcitabine-Resistant Human Cancer Cell Lines and a Broad-Spectrum of Anti-Cancer Activity “

ROCKVILLE, Md., Jan 08, 2014 (BUSINESS WIRE) — Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors. RX-3117 is a next-generation cancer cell specific drug candidate that possesses a broad spectrum of anticancer activity with reduced side effects. In an exploratory Phase I clinical trial conducted in Europe, RX-3117 demonstrated oral bioavailability, and safety and tolerability in cancer patients with solid tumors. >> FULL PR

Extended Watchlist:
CNAT, BBRY, IMMU, BLDP, NSPH, RTRX

PPHM, PLUG, & Extended Watchlist

Cannabis Sector Update
–
After an influx of new subscribers joined us over the weekend, we’d like to take this time to welcome our new friends, and try to get you up to speed as soon as possible. In a time that now spans three calendar years, we have been vigorously tracking numerous marijuana-related stocks with some very profitable results.

Last week (possibly aided by the first stores opening for sales of recreational marijuana in Colorado), the sector as a whole began to heat up once again, necessitating heavy discussion in our daily reports.  As can be expected when several sessions of frenzied uptrending carries stocks as high as we saw many of our cannabis plays, several of those stocks began to consolidate on Friday.

The exceptions were GreenGrow Technologies, Inc. GRNH, and Hemp, Inc. HEMP; High volume spread over multi-day runs often leads to high volatility as well, as in the case with HEMP, which did consolidate to a low of .021, but followed that up with a rebound back to .032, a 52% intraday swing.

GRNH continued its run from the previous session where we had witnessed a low of .045, and barreled its way to a high of .124. We’ll take overnight gains in excess of 176% any day!

As for the rest of the pot stocks we’ve been tracking that have relaxed a bit, we are still eager to see how they respond this week, and will be on the lookout for any chances we might have at bounce plays. Additionally, news of how the first week of sales went in Colorado will be sure to get even more eyes turned toward this burgeoning market sector. Check back for future updates, as we stay tuned in every step of the way.

Peregrine Pharmaceuticals, Inc. PPHM 

Speaking of stocks that we’ve been tracking since 2012, PPHM has proven itself a winner for us on multiple occasions over the years, and our most recent alert is turning out to be no different. Following that last mention, we observed a low 1.35, which at this morning’s pre-market high at 1.99 represents a 37% increase.

FDA-related news out this morning could fuel a serious push in a Northerly direction, so we won’t want to take our eyes off of PPHM for one moment as trading commences this morning.

TUSTIN, CA, Jan 06, 2014 (Marketwired via COMTEX) — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that the company has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for its lead investigational immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer (NSCLC).

“The fast track designation is a milestone for the SUNRISE trial program and represents a step closer to bringing bavituximab to the market,” said Robert Garnick, Ph.D., head of regulatory affairs at Peregrine. “We are very pleased that the FDA has recognized the potential of this novel therapy as a treatment for this serious and devastating type of cancer and look forward to working closely with them to ensure the most efficient review process.”

Plug Power, Inc. PLUG

Like the rest of the mentions in today’s newsletter, our history with PLUG goes back a long time. It has brought us percentage gains which cumulatively number in the thousands, and the New Year has brought new life for this one as well. This past Thursday, we caught PLUG at a low of 1.89, and were pleased at the solid 23% move it provided to 2.33. That figure is increasing this morning, as the stock is trading as high as 2.77 in pre-market action, a gain of 47% over Thursday’s low.

Extended Watchlist:
AMMX, PROW, EXMT, SIRI, TWGP, MSTX, SEED, CPRX, OXBT